TLR4 and metabolic dysfunction-associated steatotic liver disease: The feasibility of targeting eNAMPT/TLR4 inflammatory cascade as a therapeutic strategy for NAFLD will be underscored by ongoing Phase 1A safety and pharmacokinetic studies in healthy human volunteers.